OSLO, Norway, Feb. 19, 2025 /PRNewswire/ — Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA of NOK 8.5 million (NOK […]
Tag: Photocure
Results for the fourth quarter of 2024
OSLO, Norway, Feb. 19, 2025 /PRNewswire/ — Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA of NOK 8.5 million (NOK […]
Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025
OSLO, Norway, Feb. 17, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at […]
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
OSLO, Norway, Sept. 27, 2024 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part of the Clinigen group, in September, to […]
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
OSLO, Norway, Sept. 27, 2024 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part of the Clinigen group, in September, to […]
